Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
暂无分享,去创建一个
M. Guiguet | T. Maisonobe | B. Wallaert | Z. Amoura | J. Sibilia | E. Hachulla | L. Musset | O. Benveniste | A. Masseau | P. Hatron | M. Hamidou | A. Meyer | Y. Uzunhan | H. Nunes | S. Dubucquoi | N. Olsson | D. Adoue | H. Devilliers | B. Hervier | D. Lauque | R. Stanciu | P. Arlet
[1] O. Decaux,et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. , 2012, Autoimmunity reviews.
[2] L. Mouthon,et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. , 2012, Seminars in arthritis and rheumatism.
[3] L. Mouthon,et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. , 2011, Arthritis and rheumatism.
[4] V. Limaye,et al. Clinical heterogeneity and prognostic features of South Australian patients with anti‐synthetase autoantibodies , 2011, Internal medicine journal.
[5] T. Mimori,et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. , 2011, Respiratory medicine.
[6] C. Goulvestre,et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. , 2011, Autoimmunity Reviews.
[7] B. Wallaert,et al. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies , 2011, European Respiratory Journal.
[8] C. Oddis,et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? , 2010, Chest.
[9] B. Wallaert,et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. , 2010, Rheumatology.
[10] G. Filippatos,et al. Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .
[11] L. Rönnblom,et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. , 2009, Autoimmunity reviews.
[12] S. Sahn,et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. , 2009, Chest.
[13] Alan Julian Izenman,et al. Modern Multivariate Statistical Techniques: Regression, Classification, and Manifold Learning , 2008 .
[14] T. Mimori,et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance , 2007, Current opinion in rheumatology.
[15] M. Humbert,et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset , 2007, Thorax.
[16] Anthony Chin Loy,et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. , 2006, Arthritis and rheumatism.
[17] T. Mimori,et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies , 2006, Autoimmunity.
[18] F. Trotta,et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease , 2006, Autoimmunity.
[19] B. Schlotter-Weigel,et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies , 2004, Journal of Neurology.
[20] R. Jonsson,et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.
[21] T. Medsger,et al. Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.
[22] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[23] F. Arnett,et al. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. , 1996, Seminars in arthritis and rheumatism.
[24] M. Dalakas,et al. A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups , 1991, Medicine.
[25] J. Hughes,et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. , 1990, The Quarterly journal of medicine.
[26] J F Fries,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.
[27] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.
[28] H. Holman,et al. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). , 1972, The American journal of medicine.
[29] Arnold Simanowitz,et al. international consensus statement , 2000 .
[30] David A. Lynch,et al. Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .